Developing Programs to Counteract InfertilityWed, 09/07/2016 - 10:20
Q: One of IVINSEMER’s goals for 2016 was to increase infertility awareness in Mexico. How has the company moved forward in this regard and what communication mechanisms has it implemented?
A: IVINSEMER has worked strongly on technological advancements as becoming pioneers in the reproduction field is contingent on our investments. This led us to an alliance with the Valencian Institute of Infertility (IVI), a global solution leader. Our merger has put IVINSEMER at the forefront in both technology and human capital considering IVI’s Valencian foundation systemically works in the creation of new fertility treatments. By joining their platform our services have improved while gaining an additional capital flow.
Last year, IVINSEMER was comprised of six clinics. We now have a network of 12 with superior services. Some of them are equipped with an assisted reproduction laboratory as is the case in Mexicali, Guadalajara and Colonia Anzures in Mexico City. Franchising our brand has resulted in significant expansions in collaboration with MDs that have received IVINSEMER’s training. Future expansions include Tuxtla Gutierrez, San Luis Potosi and Oaxaca.
Q: What new treatments from IVI’s technological platform have been implemented in Mexico, and how have they been accepted in the local market?
A: Preimplantation genetic diagnosis has had positive results in the market. It allows MDs to diagnose a wide range of diseases before transferring embryos to the womb, improving its success rates by approximately 25 percent. In the past, we operated with a 50-55 percent success rate. This technology has minimized disease transfer from parent to child, such as hemophilia, anemia and cystic fibrosis to name a few.
We will soon see the entrance of the EmbryoScope solution to Mexico. It will allow us to record embryo division in real time. The incubator stores and captures their evolution taking pictures every 30 seconds and facilitating our selection process. This technology is new in Mexico and IVINSEMER will pioneer its establishment. We are the first company in Mexico to have brought life from a frozen ovule which was from a cancer patient. Through the Preserva program we bring awareness to woman that will undergo oncology treatment that our treatment will eventually allow them to become mothers.
Q: What is the strategy behind the Compromiso IVINSEMER initiative?
A: IVINSEMER has developed an accumulated pregnancy statistic throughout the years. As such, we know that couples that were successful in the treatment have a 90 percent probability of having a healthy baby. Compromiso IVINSEMER is divided into three sessions where we analyze different parameters and adapt our treatments. If couples do not reach their goals after following IVINSEMER’s medical orders the company partially reimburses them.
Q: What is the price range of your services?
A: High complexity treatments go for US$9,000 including drugs, doctor fees, diagnostics and blood tests. In the event of insufficient capital, we structure down payments and financial solutions. Unfortunately, public health institutions servicing infertility are oversaturated as the government’s agenda is not focused on the problem. Besides their lack of service availability, their infrastructure and technology is sub-par. Infertility remains a non-addressed public health issue in Mexico, giving way to private clinics like IVINSEMER.
Q: Considering fertility treatments in Mexico are considerably more affordable than in other countries, will this service increase the medical tourism influx?
A: Fertility services are attracting patients from all over the world, which we are mostly benefiting from in our Mexicali facility. We are negotiating with medical facilitators in Phoenix and San Diego to further strengthen our clinic’s reputation. As members of the Latin American Network of Assisted Reproduction (REDLARA), IVINSEMER has proven its worth and quality. Mexico is lacking certificating institutions, which has led to small companies with poor procedures that negatively impact the industry by offering deficient services.